Journal of Applied Physiology, Vol 60, Issue 4 1121-1127, Copyright © 1986 by American Physiological Society

ARTICLES

Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia

R. M. Jackson, A. J. Narkates and S. Oparil

The effects of exposing rats to hypoxia at normal atmospheric pressure for periods of 21-24 days on intrapulmonary conversion of angiotensin I (ANG I) to angiotensin II (ANG II) were examined using an isolated rat lung preparation perfused at constant flow. 125I-ANG I (160 fmol) was injected alone and with graded doses (0.1, 1.0, and 100 nmol) of unlabeled ANG I into the pulmonary artery, and the effluent was collected for measurement of ANG I, ANG II, and metabolites. At low doses of injected ANG I (125I-ANG I alone or with 0.1 or 1.0 nmol unlabeled ANG I), the percent conversion of ANG I to ANG II was 67.5 +/- 2.1 (SE), 65.1 +/- 2.0, and 62.5 +/- 1.6 in 21-day hypoxia-exposed animals and 83.8 +/- 2.7, 81.4 +/- 3.9, and 79.6 +/- 2.3 (P less than 0.01) in control rats maintained under normoxic conditions. At the highest dose (100 nmol) of injected ANG I, percent conversion was reduced in both hypoxic and control groups to 46.8 +/- 5.0 and 64.0 +/- 6.0, respectively (P less than 0.05). Mean transit times of labeled material through the pulmonary circulation were not significantly different in hypoxic vs. normoxic lungs at any ANG I load, suggesting that the decreased conversion seen in hypoxic lungs was not related to altered kinetics of substrate exposure. Thus chronic hypoxia is associated with significant inhibition of transpulmonary ANG I conversion that is independent of perfusate flow. We postulate that this phenomenon is due to alterations at the endothelial membrane level.

This article has been cited by other articles:

				R. P. Marshall, P. Gohlke, R. C. Chambers, D. C. Howell, S. E. Bottoms, T. Unger, R. J. McAnulty, and G. J. Laurent Angiotensin II and the fibroproliferative response to acute lung injury Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L156 - L164. [Abstract] [Full Text] [PDF]

				D. R. Woods, A. J. Pollard, D. J. Collier, Y. Jamshidi, V. Vassiliou, E. Hawe, S. E. Humphries, and H. E. Montgomery Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene and Arterial Oxygen Saturation at High Altitude Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 362 - 366. [Abstract] [Full Text] [PDF]

				M. Pfeifer, G. Bruckschlegel, S. R Holmer, M. Paul, A.J.G. Riegger, and H. Schunkert Reciprocal regulation of pulmonary and cardiac angiotensin-converting enzyme in rats with severe left ventricular hypertrophy Cardiovasc Res, April 1, 1998; 38(1): 125 - 132. [Abstract] [Full Text] [PDF]

				S. Prié, T. K. Leung, P. Cernacek, J. W. Ryan, and J. Dupuis The Orally Active ETA Receptor Antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) Prevents the Development of Pulmonary Hypertension and Endothelial Metabolic Dysfunction in Monocrotaline-Treated Rats J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1312 - 1318. [Abstract] [Full Text]